SCHEMBL17339199

SCHEMBL17339199

C[C@H](NC1=C(C(=O)O)CCC1)c1ccccc1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 1/20 0.46
KDM4E B2RXH2 6/20 0.45
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
CYP1A2 P05177 1/20 0.45
CYP3A4 P08684 1/20 0.45
LMNA P02545 3/20 0.44
EPHX1 P07099 2/20 0.44
TAAR1 Q96RJ0 2/20 0.44
POLB P06746 1/20 0.44
RECQL P46063 1/20 0.44
KDM4C Q9H3R0 1/20 0.43
ASPH Q12797 2/20 0.43
KDM8 Q8N371 2/20 0.43
RIOX2 Q8IUF8 1/20 0.42
NPC1 O15118 1/20 0.41
FABP4 P15090 1/20 0.41
FABP5 Q01469 1/20 0.41
HSD17B10 Q99714 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6719047 1.00 CYP2D6 (0.46) CYP2D6KDM4EMEN1KMT2ACYP1A2
SCHEMBL1044302 0.97 CYP2D6 (0.49) CYP2D6KDM4EMEN1KMT2ACYP1A2
SCHEMBL6725960 0.97 CYP2D6 (0.49) CYP2D6KDM4EMEN1KMT2ACYP1A2
SCHEMBL18946078 0.87 SLC6A3 (0.46) CYP2D6KDM4EMEN1KMT2ACYP1A2
SCHEMBL10305737 0.87 RECQL (0.44) KDM4EMEN1KMT2ACYP1A2CYP3A4
SCHEMBL17339168 0.84 DHODH (0.46) KDM4EMEN1KMT2APOLBNPC1
SCHEMBL30782219 0.82 ALOX5 (0.50) KDM4EMEN1KMT2ACYP1A2CYP3A4
SCHEMBL6717708 0.80 KDM4C (0.40) CYP2D6KDM4EMEN1KMT2ACYP1A2
SCHEMBL28748164 0.80 KDM4C (0.40) CYP2D6KDM4EMEN1KMT2ACYP1A2
SCHEMBL10137636 0.79 ALOX5 (0.50) CYP2D6KDM4EMEN1KMT2ACYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10112973-B2 Process for the preparation of ramipril SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2018-10-30 US disclosed
EP-3154940-B1 PROCESS FOR THE PREPARATION OF RAMIPRIL SANOFI AVENTIS DEUTSCHLAND (DE) 2018-04-18 EP disclosed
US-20170158733-A1 PROCESS FOR THE PREPARATION OF RAMIPRIL SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2017-06-08 US disclosed
US-20170158733-A1 PROCESS FOR THE PREPARATION OF RAMIPRIL SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2017-06-08 US disclosed
EP-3154940-A1 PROCESS FOR THE PREPARATION OF RAMIPRIL Sanofi-Aventis Deutschland GmbH (DE) 2017-04-19 EP disclosed
WO-2015189108-A1 PROCESS FOR THE PREPARATION OF RAMIPRIL SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2015-12-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10112973-B2 Process for the preparation of ramipril CYP2S1, CYP3A5, CYP4B1 CYP2D6 9/4885KDM4E 789/4885MEN1 4797/4885
US-20170158733-A1 PROCESS FOR THE PREPARATION OF RAMIPRIL CYP2S1, CYP3A5, CYP4B1 CYP2D6 9/4885KDM4E 789/4885MEN1 4797/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.